Imprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis’ Ophthalmic Portfolio Market

Source: Imprimis Pharmaceuticals

Tuesday, April 18, 2017 | Partnerships , Imprimis Pharmaceuticals


Imprimis Pharmaceuticals and Cameron Ehlen Group, d/b/a Precision Lens, announced the signing of a 3-year exclusive sales representation agreement. Under the agreement, Precision Lens will deploy a dedicated sales team to introduce Imprimis’ ophthalmic portfolio into select geographies in the US, primarily focused in 13 states in the U.S. Midwest. 

Precision Lens, which sells and distributes more than 60 percent of the IOLs for cataract surgery in its markets, will add resources to exclusively sell Imprimis’ pharmaceutical products, including Dropless Therapy, LessDrops combination eye drops, Simple Drops preservative-free glaucoma drops, MKO Melt conscious sedation, and medications typically used for dilation, general inflammation and infection. Imprimis will continue to focus its sales efforts in all 50 states and provide support to new accounts procured by Precision Lens.    

“With more than 60 percent IOL market share and a long track record of earning their customer's respect through exceptional service, expertise and integrity, we could not want for a better partner to help us bring our innovative family of ophthalmic products to more physicians, large practice groups, surgery centers and hospitals," Mark L. Baum, CEO of Imprimis, said in a news release. "We look forward to working with Precision Lens and believe this important relationship will increase sales productivity and strengthen our position in this important region of the country. Precision Lens will be a key partner as we introduce our Simple Drops glaucoma program in the second quarter and our new dry eye program, expected to launch in the second half of the year. Precision Lens’ mission to offer eye care providers the best technology options available in the marketplace marries perfectly with the Imprimis commitment of providing patients with affordable access to innovative and high-quality medications.”  

“We are very selective about the companies we represent and believe the portfolio of innovative ophthalmic medications from Imprimis, including those made from its FDA-registered outsourcing facility, will be very well-received by our customers," Paul Ehlen, CEO of Precision Lens, said in the news release. "For over 27 years we have been successfully representing leading ophthalmology companies and providing healthcare professionals with a wide array of innovative solutions for the care of their patients. We are excited to deploy a dedicated team to exclusively promote Imprimis’ portfolio within our territory. Imprimis’ Dropless Therapy and LessDrops combination drops have the potential to become standard-of-care in the post-cataract surgery market. This, combined with the soon to be introduced preservative free glaucoma offerings and new dry eye medications, provide us with the value and innovation we strive to provide our customers.”


Comments

You must be logged in to leave a comment.